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eapolWe conducted a retrospective study of 155 children who underwent unrelated donor hematopoietic cell
transplantation (HCT) between 1990 and 2005 for acute lymphoblastic leukemia in third remission. The
median patient age was 11 years, the median time from diagnosis to first relapse was 36 months, and the
median time from first relapse to second relapse was 26 months. Stem cell sources were bone marrow
(n 5 115), peripheral blood (n 5 11), and cord blood (n 5 29). All patients received a myeloablative pre-
transplantation conditioning regimen. The 5-year estimates of leukemia-free survival, relapse, and nonre-
lapse mortality were 30%, 25%, and 45%, respectively. In multivariate analysis, the only risk factor
associated with relapse was the interval between the first relapse and the second relapse. Second relapses
occurring .26 months from the first relapse were associated with lower risk for post-HCT relapse com-
pared with second relapses occurring at #26 months (relative risk, 0.4; P 5 .01). Relapse risk was lowest
when late second relapse was preceded by late first relapse (.36 months from diagnosis), as demon-
strated by a 3-year relapse rate of 9% (P 5 .0009). Our data indicate that long-term leukemia-free survival
can be achieved in children with acute lymphoblastic leukemia in third remission using unrelated donor
HCT, especially when the second relapse occurs late.
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Table 1. Characteristics of 155 Patients Undergoing Un-
related Hematopoietic Cell Transplantation for Acute Lym-
phoblastic Leukemia in Third Remission
Characteristic
Age at transplantation in years, median
(range)
11 (1-18)
1-10 years 70 (45)
11-18 years 85 (55)
Male sex, n (%) 93 (60)
Pretransplantation performance score
<90%, n (%)*
31 (20)
Disease, n (%)
Pre-B or B cell lineage ALL 114 (74)
T cell ALL 8 (5)
Unknown 33 (21)
Cytogenetic abnormalities before
transplantation, n (%)†
High risk 8 (5)
Others 43 (28)
No abnormalities 42 (27)
Unknown 62 (40)
Time from diagnosis to first relapse in
months, median (range)
35 (1-126)
#36 months 78 (50)
>36 months 76 (49)
Unknown 1 (1)
Time from first relapse to second
relapse in months, median (range)
26 (4-116)
#26 months 77 (50)
>26 months 78 (50)
Time from diagnosis to transplantation
in months, median (range)
61 (11-167)
#24 months 20 (13)
25-48 months 34 (22)
49-72 months 38 (25)
73-96 months 29 (19)
>96 months 34 (22)
1834 Biol Blood Marrow Transplant 17:1833-1840, 2011E. R. Nemecek et al.followed by allogeneic HCT [4-7]. The current
consensus approach is to recommend allogeneic
HCT for patients with ALL in second remission for
whom a matched sibling donor is available, and to
consider alternative donor transplantation for those
who experience early first relapse (#36 months) or
who are otherwise at high risk for relapse based on
disease characteristics or response to reinduction
therapy.
Outcomes for children and adolescents with ALL
who experience a second relapse after chemotherapy
are inferior to those with earlier stages of disease [8].
Fewer patients achieve a third remission, and the use
of allogeneic HCT in patients who are unable to
achieve remission show very poor outcomes [9,10].
When third remissions are attained, they are not
expected to be sustainable by chemotherapy alone,
and the recommendation has generally been to
proceed to HCT with any available donor, usually an
unrelated volunteer adult donor or cord blood. The
few previous reports on a limited number of patients
[11-13] suggest a role for allogeneic HCT in
children with ALL in third remission, but this has
not been studied in a larger cohort.
The goals of the present study were to determine
the outcome of children undergoing unrelated donor
HCT for ALL in third remission and to identify prog-
nostic factors that affect post-HCT relapse and LFS
using data reported to a large, international coopera-
tive registry.ALL indicates acute lymphoblastic leukemia.
*Pretransplantation performance score was reported using Lansky-Play
performance score for patients younger than 16 years and Karnofsky
score for patients 16 and older.
†Cytogenetic abnormalities were considered high risk if any of the fol-
lowing abnormalities were present: t(4,11), t(9,22), hypodiploidy/near
triploloidy or >5 abnormalities.
Table 2. Sites of First and Second Leukemia Relapses
Site of First
Relapse
Site of Second Relapse, n (%)
BM ±
Extramedullary
Isolated
CNS
Other
Extramedullary
BM ± extramedullary site 47 (30) 3 (2) 0
Isolated CNS 6 (4) 6 (4) 0
Other extramedullary sites 6 (4) 0 3 (2)
Unknown 70 (45) 11 (7) 3 (2)
BM indicates bone marrow; CNS, central nervous system.PATIENTS AND METHODS
Patient and Disease Characteristics
This report is based on data contributed by 57
transplant centers to the Center for International
Blood and Marrow Transplant Research. The 155 pa-
tients analyzed were age 1-18 years and received an un-
related donor HCT between January 1990 and
December 2005 for ALL in third complete remission.
Twenty-one recipients of previous HCTwho relapsed
and then underwent a second HCT while in third re-
mission were excluded because there were too few of
these patients to be analyzed in a separate category.
Eighteen of the 21 patients died; recurrent leukemia
was the most frequent cause of death, and others
died of organ failure or infection. Almost all deaths
occurred within the first year after the second trans-
plantation. The characteristics of patients included in
the current analysis are summarized in Table 1. The
majority of patients (74%) had B cell lineage ALL.
One-half of the patients experienced a first relapse
within 36 months of the initial diagnosis, and one-
half experienced a second relapse within 26 months
of the first relapse. The median time from diagnosis
to transplantation was 61 months (range, 11-167months). Table 2 summarizes the sites of first and sec-
ond relapses in all patients. For 83% of the patients,
the site of second relapse was the bone marrow with
or without associated extramedullary involvement.
Consent for reporting and inclusion in study re-
ports was obtained by participating centers at the
time of transplantation. Data are reported to the Cen-
ter for International Blood and Marrow Transplant
Research at transplantation and at predefined intervals,
including annual follow-ups. The Institutional Review
Biol Blood Marrow Transplant 17:1833-1840, 2011 1835Unrelated HCT for Childhood ALL in Third RemissionBoards of the Medical College of Wisconsin and the
NationalMarrowDonor Programapproved this study.Transplant Characteristics
Transplant characteristics are summarized in
Table 3. The unrelated donor stem cell sources in-
cluded bone marrow (74%), peripheral blood stem
cells (PBSCs; 7%), and cord blood (19%). Donor–
recipient pairs considered well matched were defined
as having no known disparity at human leukocyte anti-
gen (HLA) -A, -B, -C, and -DRB1; those considered
partially matched were defined as having 1 known or
1 likely disparity; and those considered mismatchedTable 3. Transplant Characteristics
Characteristic n (%)
Conditioning regimen*
TBI + cyclophosphamide ± other 138 (89)
TBI + other 5 (3)
Busulfan + cyclophosphamide ± other 10 (6)
Busulfan + melphalan 2 (1)
Donor–recipient sex match
Male donor–male recipient 50 (32)
Male donor–female recipient 32 (21)
Female donor–male recipient 43 (28)
Female donor–female recipient 30 (19)
Donor–recipient cytomegalovirus status
Donor (2)–recipient (2) 64 (41)
Donor (+)–recipient (2) 22 (14)
Donor (2/+)–recipient (+) 51 (33)
Unknown 18 (12)
Graft type/HLA matching†
Bone marrow/PBSC 115 (74)/11 (7)
Well matched 40 (32)
Partially matched 36 (28)
Mismatched 50 (40)
Cord blood 29 (19)
Well matched 1 (3)
Partially matched 6 (21)
Mismatched 22 (76)
Year of transplantation
1990-1994 32 (21)
1995-1999 52 (34)
2000-2005 71 (46)
Therapy given as conditioning or GVHD
prophylaxis
ATG 80 (52)
Alemtuzumab 9 (6)
GVHD prophylaxis‡
T cell depletion 48 (31)
Tacrolimus + other 17 (11)
Cyclosporine + methotrexate ± other 67 (43)
Cyclosporine ± other 23 (15)
TBI indicates total body irradiation; HLA, human leukocyte antigen;
PBSC, peripheral blood stem cell; GVHD, graft-versus-host disease;
ATG, antithymocyte globulin.
*TBI + cyclophosphamide6 other (n 5 106), TBI + cyclophosphamide
+ etoposide (n5 32), TBI + other (n5 4), TBI + etoposide (n5 1); TBI
dose #1300 Gy (n 5 65), TBI dose >1300 Gy (n 5 78).
†Donor–recipient well matched is defined as no known disparity be-
tween donor and recipient at HLA-A, -B, -C, and -DRB1, partially
matched as one known or one likely disparity andmismatched as$2 dis-
parities. Seventy patients had high-resolution HLA typing information.
‡Cyclosporine + corticosteroids (n 5 10), cyclosporine + corticoste-
roids + ATG (n5 5), cyclosporine alone (n5 4), cyclosporine + myco-
phenolate (n 5 3), cyclosporine + ATG (n 5 1).were defined as having 2 or more disparities [14].
Bone marrow and PBSC grafts were matched in 32%
of cases and mismatched at 1 or 2 loci in 68% of cases.
Cord blood grafts were all single units and were 6/6
matched in 3% of cases and mismatched at 1 or 2
loci in 97% of cases.
All recipients received a myeloablative preparative
regimen. Preparative regimens varied, but 92% con-
tained total body irradiation (TBI); of the 143 recipi-
ents who received TBI, 65 (45%) received a TBI dose
\1300 cGy and 78 (55%) received a dose $1300
cGy. Most recipients (69%) received a calcineurin in-
hibitor for graft-versus-host disease (GVHD) prophy-
laxis. Eighty-nine of 155 recipients (57%) received
in vivo T cell depletion, achieved in 80 cases using an-
tithymocyte globulin (ATG). Of the 115 bone marrow
grafts, 48 (42%) were T cell depleted using ex vivo
methods. Both forms of T cell depletion were used
for 21% of the transplants, because 33 recipients of
ex vivo T cell–depleted bone marrow received ATG.Statistical Analysis
The time of neutrophil recovery was defined as the
first of 3 consecutive days with an absolute neutrophil
count .0.5  109/L. Platelet recovery was defined
as the first of 3 consecutive days with a platelet count
.20 109/L and transfusion-independence for at least
7 days. Acute and chronic graft-versus-host disease
(GVHD) were graded as described previously
[15,16]. Nonrelapse mortality (NRM) was defined as
death due to causes other than recurrent leukemia.
Probabilities of overall survival (OS) and LFS were
calculated using Kaplan-Meier product limit estimates
[17]. Relapse or death was considered failure for the
endpoint of LFS. Cumulative incidence estimates
were used to calculate the rates of hematopoietic recov-
ery, GVHD, relapse, andNRM [18]. Cox proportional
hazard regression models were fit for the endpoints
LFS, relapse,NRM, andGVHD [19]. Exploratory var-
iables chosen for regression models included patient
age, sex, and pretransplantation performance score;
disease characteristics, including time from diagnosis
to first relapse, time from first relapse to second re-
lapse, and site(s) of second relapse; transplant charac-
teristics such as use of TBI, donor–recipient sex
match, donor–recipient cytomegalovirus status, degree
of HLA matching, graft type, year of transplantation,
and use of T cell depletion or ATG. A backward-
stepwise model selection approach was used to identify
potential significant risk factors. Variables that reached
a 5% level of significance were kept in the final model.
The effect of acute and chronic GVHD on relapse and
LFS was evaluated by treating GVHD as a time-
dependent covariate in the final regression models.
All P values are 2-sided. Analyses were done using
SAS version 9.1 (SAS Institute, Cary, NC).
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Hematopoietic Recovery
Out of 155 patients, 147 achieved neutrophil re-
covery, with a median time to recovery of 18 days.
The day 128 and day 1100 posttransplantation
incidences of neutrophil recovery were 84% (95%
confidence interval [CI], 77%-89%) and 95% (95%
CI, 90%-98%), respectively. All 8 patients who
failed to achieve neutrophil recovery died from
a transplantation-related cause before day1100 post-
transplantation. Seven of these patients received
a mismatched bone marrow (n 5 3) or cord blood
(n 5 4) grafts; ATG was included in the transplant-
conditioning regimen for 4 patients. Ninety-four
of 155 patients achieved platelet recovery, with
a median time to recovery of 32 days. The day 1100
incidence of platelet recovery was 64% (95% CI,
56%-72%).GVHD
Ninety patients developed grade B-D acute
GVHD. The day 1100 incidence of grade B-D
acute GVHD was 58% (95% CI, 50%-66%). In
multivariate analysis, the risk of acute GVHD was
higher in male recipients of female donors, recipi-
ents of non–TBI-containing regimens, patients
with a low pretransplantation performance score,
and those who did not receive ATG (Table 4).
Forty-one patients developed chronic GVHD; the
5-year incidence of chronic GVHD was 28% (95%
CI, 21%-35%). In multivariate analysis, graft type
was the sole risk factor identified; transplantation
of PBSC grafts was associated with the highest risk
(Table 4).Table 4. Multivariate Analysis of Acute and Chronic GVHD
Independent Variable n RR (95% CI) P Value
Acute GVHD
Donor–recipient sex match
Female donor–male recipient 43 1.00
Other 110 0.53 (0.33-0.85) .009
Conditioning regimen
TBI-containing 142 1.00
Non–TBI-containing 11 3.25 (1.57-6.73) .001
Pretransplantation performance
score
#90% 31 1.00
>90% 117 0.43 (0.25-0.73) .002
ATG given
No 73 1.00
Yes 80 0.65 (0.42-0.99) .044
Chronic GVHD
Graft type P-overall 5 .011
Bone marrow 109 1.00
PBSC 11 2.85 (1.18-6.92) .02
Cord blood 29 0.43 (0.15-1.21) .11
GVHD indicates graft-versus-host disease; TBI, total body irradiation;
ATG, antithymocyte globulin; PBSC, peripheral blood stem cell.Survival, Relapse, and NRM
At the last follow-up (median, 75 months; range,
44-170 months), 47 of the 155 patients were alive.
The 5-year probabilities of OS and LFS were 31%
(95% CI, 24%-39%) and 30% (95% CI, 22%-37%),
respectively. Thirty of 155 patients had died from re-
lapse, and the 5-year incidence of posttransplantation
relapse was 25% (95% CI, 19%-33%). Seventy-eight
of 155 patients (50%) had died from causes other than
leukemia recurrence. The day1100, 1-year, and 5-year
NRM incidences were 19% (95%CI, 14%-26%), 41%
(95% CI, 33%-49%), and 45% (95% CI, 37%-53%),
respectively. Causes of death are summarized in
Table 5. Pulmonary and other organ toxicity accounted
for 43% of the NRM, with deaths distributed evenly
before and after day 100. Infection and GVHD ac-
counted for 18% and 17% of the deaths attributed to
NRM, respectively.
In multivariate analysis, the only significant risk
factor associated with relapse was the interval between
first and second relapse (Figure 1). Patients were con-
sidered to have an early second relapse if the interval
between the first and second relapses was#26months,
and as late relapse if the interval between the first and
second relapses was .26 months. Patients with a late
second relapse had a lower risk for relapse compared
with those with early second relapse (relative risk,
0.4; 95% CI, 0.21-0.78, P 5 .01). The effect of time
from diagnosis to first relapse was also examined
(Table 6). Patients were considered to have an early
first relapse if the time from diagnosis to first relapse
was #36 months and to have a late first relapse if this
time was.36 months. The lowest incidence of relapse
posttransplantation was seen in patients who experi-
enced a late first relapse and a late second relapse
(5-year relapse rate, 9%; 95% CI, 3%-19%; P 5
.0009). There were no significant differences in the
site of relapse across groups experiencing late or early
first relapse or late or early second relapse. Estimates
of LFS and NRM are shown in Figures 2 and 3.Table 5. Causes of Death
Cause of Death Number <Day 100 >Day 100
Total deaths 108 33 75
Leukemia 30 1 29
Graft failure 3 2 1
Infection 14 5 9
Pulmonary toxicity (IPS, ARDS) 16 8 8
Other (nonlung) organ failure/toxicity 17 7 10
Secondary malignancy 5 0 5
Hemorrhage/vascular 8 4 4
GVHD ± infection 13 6 7
Unknown 2 0 2
IPS indicates idiopathic pneumonitis syndrome; ARDS, acute respiratory
distress syndrome; GVHD, graft-versus-host disease.
Five patients died from secondary cancers, including 3 brain tumors,
1 Epstein-Barr virus-induced lymphoproliferative disease, and 1 of un-
known type.
Figure 1. Cumulative incidence of posttransplantation relapse.
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models for LFS and NRM and found to not be
statistically significant were time from diagnosis to
first relapse, site of second relapse, recipient age and
sex, performance score, degree of HLA matching,
graft source, use of ATG or ex vivo T cell depletion,
and presence of acute or chronic GVHD.DISCUSSION
Risk stratification of newly diagnosed childhood
ALL has changed the role of allogeneic HCT for
ALL in first remission [20,21]. Thus, allogeneic
HCT for first remission ALL is generally confined
to those children considered at very high risk for
relapse [22]. Children who experience relapsed ALL
within 36 months from diagnosis and who achieve
a second remission usually undergo allogeneic HCT
if a matched sibling donor is available. However, prac-
tice variation exists across the country, and 50% of the
children in our cohort with early (mostly marrow) re-
lapse did not proceed to HCT in second remission,
which would have been considered best practice.
These patients lacked an HLA-matched sibling, and
the treating physician deferred unrelated donor trans-
plantation. For children who do not undergo HCT in
second remission but relapse and achieve a third remis-
sion, alternative donor HCT has been considered the
option offering the best chance for cure; however,Table 6. Probability of Outcomes Across Groups Defined by Time f
Second Relapse
Months from Diagnosis to First Relapse #36
Months from First Relapse to Second Relapse #26
Number 55
3-year LFS 32 (20-44) 3
3-year OS 34 (21-46) 4
3-year relapse 33 (21-46) 3
3-year NRM 35 (23-47) 3
LFS indicates leukemia-free survival; OS, overall survival; NRM, nonrelapse monly limited data are available. Because ALL therapy
continues to be risk-adapted, it is reasonable to expect
that pediatric referrals for alternative donor HCT to
treat ALL in third remission will increase in the com-
ing years.
A randomized or prospective therapeutic study of
this patient group has not yet been conducted, and
retrospective reviews to date have been limited to small
studies [11-13]. Borgmann et al. [11] reported on
a subset of 33 children undergoing bone marrow
transplantation for ALL in third remission in Europe
between 1983 and 1995. They found an LFS of
48% and an NRM of 30%, with worse outcomes
when second relapse occurred within 6 months after
completion of previous therapy. In contrast, patients
whose second relapse occurred later had an LFS of
61%, comparable to that seen in the same study for
patients who underwent HCT for ALL in second
remission. Afify et al. [12] reported on their single-
institution experience with a similar group of patients
in the United Kingdom. They found that shorter
duration of second remission (\30 months) was asso-
ciated with lower LFS and higher NRM. Shorter
duration of remission and the presence of extramedul-
lary disease also were associated with a higher risk
of posttransplantation relapse. Most recently, Gassas
et al. [13] reported on the Canadian experience and
found that LFS in a group of 22 children was 32% and
that most leukemia-free survivors had chronicGVHD,
suggesting a role for the graft-versus-leukemia effect
in survivors.
Our study represents the largest, most comprehen-
sive analysis to date of the outcome of children under-
going unrelated donor HCT for ALL in third
remission. We found an LFS rate of 30% that was
not influenced by disease characteristics, donor or
stem cell source, conditioning, or graft manipulation.
Of particular interest, only 26% of the cohort had
a well-matched graft, yet HLA match and graft source
did not influence LFS. Accurate assessment of the im-
pact of donor–recipient HLA matching on transplan-
tation outcomes typically requires the study of
thousands of patients; consequently, donor selection
practices should follow the recommendations of thoseromDiagnosis to First Relapse and Time from First Relapse to
Probability (95% CI) P value
#36 >36 >36
>26 #26 >26
23 22 54
0 (13-49) 18 (6-36) 35 (23-48) .43
3 (23-62) 20 (6-40) 39 (26-51) .32
5 (17-55) 36 (17-56) 9 (3-19) .0009
5 (17-54) 45 (24-64) 56 (41-68) .12
ortality.
Figure 2. Estimates of leukemia-free survival.
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that information on site of relapse (first and second)
was not reported for a substantial number of patients.
Although it is possible that the relatively small num-
bers did not allow for adequate comparisons between
subgroups, our results support the recommendation
that patients with ALL in third remission, especially
those with long intervals between first and second
relapse, should proceed to HCT as soon as they
achieve third complete remission with the best alterna-
tive donor available.
Relapse rates were lowest in the group of children
who experienced late first relapse and late second
relapse, likely indicative of more sensitive disease com-
pared with other cohorts.We found no survival advan-
tage for patients with chronic GVHD, as has been
suggested by other reports [13]. However, others
have demonstrated graft-versus-leukemia effects after
allogeneic HCT for ALL, and our inability to demon-
strate this phenomenon might be attributed to the rel-
atively small number of patients with chronic GVHD
in this study.
Perhaps our most sobering finding is that NRM
was high in all patients regardless of time to relapse
and that in the group of patients with the lowest relapse
risk, this high NRM negated any survival advantage.
We observed NRM rates higher than those reported
for patients with ALL in second remission afterFigure 3. Estimates of nonrelapse mortality.matched sibling or unrelated donor HCT [5-7]. In our
cohort, 42% of nonrelapse deaths were attributable to
organ toxicity, suggesting that the cumulative effects
of pretransplantation reinduction therapies might
mitigate some of the survival benefits provided by
allogeneic HCT for third remission ALL. Perhaps
another important message from this finding of high
NRM after HCT in third remission ALL is to
preferably offer HCT to as many children as possible
in second rather than third complete remission. Our
cohort was notable for the 50% in whom first relapse
occurred\36 months from diagnosis, and assuming
that most of these children had marrow relapse, they
would have met the conventional criteria for HCT in
second remission. It is possible that absence of
a well-matched donor might have been the reason
that some children did not undergoHCT in second re-
mission, but this rationale would now be questionable
given current outcomes for alternative donor HCT.
Given that reduced-intensity conditioning
(RIC) has now been explored for children and adults
with ALL, such strategies might be considered for
heavily pretreated children undergoing HCT for
third remission ALL [23-26]. A question for future
investigations is whether LFS in these children can
be improved if one attempted to balance the known
higher relapse rates associated with RIC and the
expected abrogation of higher NRM rates that
follow myeloablative conditioning. Unfortunately,
our finding of an increase in NRM from 19% at day
1100 to 45% at 5 years in our cohort does not
clearly support the hypothesis that RIC approaches
will necessarily offset NRM and improve survival.
The second major cause of NRM in our study was
infection without GVHD (18% of NRM), with 9
of the 14 deaths occurring after day 100, which
suggests that delayed reconstitution of immunity
might be responsible. This result is not surprising,
given that at least one-half of the children had
received in vivo or ex vivo T cell depletion and 21%
had received both forms of T cell depletion. Taken
together, these findings suggest that it will be
particularly important in this high-risk group to try
and minimize peritransplantation approaches that
impede immune reconstitution and to also consider
approaches thatmight augment infection prophylaxis.
Finding the proper balance might be challenging,
because our finding of considerably lower mortality
fromGVHD compared with other reports in children
with ALL also can be readily explained as a benefit
of these T cell–depletion strategies [7,9].
We conclude that long-term LFS is achievable in
children after unrelated donor HCT for ALL in third
remission. However, HCT in third remission is not
an optimal strategy, because of the high NRM rate,
which implies that when an HLA-matched sibling is
lacking, a more desirable option is HCT in second
Biol Blood Marrow Transplant 17:1833-1840, 2011 1839Unrelated HCT for Childhood ALL in Third Remissionremission with the best available alternative donor.
When considering HCT in third remission, it is im-
portant to carefully consider the impact of one or
more T cell–depletion approaches on delayed im-
mune reconstitution and, at the very least, incorpo-
rate augmented infection prophylaxis strategies. In
addition, posttransplantation relapse prevention
strategies should be considered, with possible options
including the use of donor lymphocyte infusions and/
or small-molecule inhibitors (eg, tyrosine kinase in-
hibitors) or other new agents, either prophylactically
or preemptively triggered by the results of sensitive
and specific minimal disease monitoring.ACKNOWLEDGMENTS
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